-
81
Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non‐small‐cell lung cancer
Published 2023-05-01Get full text
Article -
82
-
83
-
84
Long COVID Clinical Severity Types Based on Symptoms and Functional Disability: A Longitudinal Evaluation
Published 2024-03-01Get full text
Article -
85
-
86
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlle...
Published 2016“…We hypothesised that fevipiprant (QAW039), an antagonist of prostaglandin D2 receptor 2, might reduce eosinophilic airway inflammation in patients with moderate-to-severe eosinophilic asthma.We performed a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial at Glenfield Hospital (Leicester, UK). We recruited patients with persistent, moderate-to-severe asthma and an elevated sputum eosinophil count (≥2%). …”
Journal article -
87
-
88
-
89
-
90
-
91
-
92
-
93
Mapping brain endophenotypes associated with idiopathic pulmonary fibrosis genetic riskResearch in context
Published 2022-12-01Get full text
Article -
94
-
95
Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CE...
Published 2010“…SETTING: The ECMO centre at Glenfield Hospital, Leicester, and approved conventional treatment centres and referring hospitals throughout the UK. …”
Journal article -
96
The genomics of heart failure: design and rationale of the HERMES consortium
Published 2021-12-01Get full text
Article -
97
-
98
Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
Published 2024-01-01Get full text
Article -
99
Natural history and outcomes in paediatric RASopathy‐associated hypertrophic cardiomyopathy
Published 2024-04-01Get full text
Article -
100